Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Infinity Pharmaceuticals Inc Announces Pricing Of Secondary Offering Of Common Stock


Thursday, 11 Apr 2013 08:15am EDT 

Infinity Pharmaceuticals Inc announced the pricing of an underwritten public offering of common stock by existing shareholders Beacon Company and Rosebay Medical Company L.P., including shares that were transferred to Beacon and Rosebay by Purdue Pharma L.P., an associated company of Beacon and Rosebay, at a public offering price of $40.00 per share. The aggregate size of the offering is 10,000,000 shares, with 5,000,000 shares of common stock offered by Beacon, and 5,000,000 shares of common stock offered by Rosebay. The selling shareholders have also granted the underwriters an option for 30 days to purchase from the selling shareholders up to an additional 1,416,565 shares to cover over-allotments, if any. Assuming closing of this offering and assuming that the over-allotment option is not exercised, Beacon, Rosebay and Purdue collectively own an aggregate of 2.96% of Infinity's outstanding common stock. The offering is expected to close on or about April 16, 2013, subject to the satisfaction of customary closing conditions. Infinity will not sell any shares or receive any proceeds from the offering, and the total number of shares of outstanding common stock will not change as a result of the offering. The joint book-running managers for the proposed offering are Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC. 

Related Company News

Company Quote

9.27
-0.4 -4.14%
28 Jul 2014